Moleculin Biotech Inc
NASDAQ:MBRX
Intrinsic Value
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of MBRX.
Moleculin Biotech Inc's market capitalization is 9.6m USD.
MBRX stock price is 4.3082 USD.
MBRX.
MBRX. Open DCF Valuation
MBRX. Open Relative Valuation
MBRX has upside potential of 712% compared to the average analyst price target.
Open Wall St Estimates
MBRX has negative Free Cash Flow for the last twelve months.
MBRX has negative Operating Income for the last twelve months.
MBRX has negative Net Income for the last twelve months.
MBRX's ROE (Return on Equity) has significantly decreased in the last 3 years from -40% to -76%, and is approaching profitability.
MBRX's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -172% to -243%, and is approaching profitability.
MBRX's ROE (Return on Equity) for the past 12 months is negative and is equal to -76%.
MBRX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -243%.
MBRX's long-term assets (38m USD) exceed its long-term liabilties (12m USD).
MBRX's short-term assets (26m USD) exceed its short-term liabilties (7m USD).
MBRX has negative three-year average ROE (Return on Equity): -47%. The company is not efficient at transforming stockholders' equity into net income.
MBRX has negative three-year average ROIC (Return on Invested Capital): -216%. The company is not efficient at using invested capital to generate operating income.
MBRX's D/E (Debt to Equity) is very low and is equal to 0.
MBRX's Altman Z-Score is very low and is equal to -6.09.
Fundamental Analysis
Moleculin Biotech Inc
Balance Sheet Decomposition
Moleculin Biotech Inc
| Current Assets | 26.3m |
| Cash & Short-Term Investments | 23.6m |
| Receivables | 1.5m |
| Other Current Assets | 1.2m |
| Non-Current Assets | 11.9m |
| PP&E | 796k |
| Intangibles | 11.1m |
| Current Liabilities | 6.8m |
| Accounts Payable | 2.5m |
| Accrued Liabilities | 4.3m |
| Other Current Liabilities | 60k |
| Non-Current Liabilities | 5.3m |
| Other Non-Current Liabilities | 5.3m |
Earnings Waterfall
Moleculin Biotech Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-29.6m
USD
|
|
Operating Income
|
-29.6m
USD
|
|
Other Expenses
|
-138k
USD
|
|
Net Income
|
-29.8m
USD
|
Free Cash Flow Analysis
Moleculin Biotech Inc
MBRX Profitability Score
Profitability Due Diligence
Moleculin Biotech Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Moleculin Biotech Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
MBRX Solvency Score
Solvency Due Diligence
Moleculin Biotech Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Moleculin Biotech Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MBRX Price Targets Summary
Moleculin Biotech Inc
According to Wall Street analysts, the average 1-year price target for
MBRX
is 35 USD
.
Ownership
MBRX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
MBRX Price
Moleculin Biotech Inc
| Average Annual Return | -37.31% |
| Standard Deviation of Annual Returns | 22.9% |
| Max Drawdown | -97% |
| Market Capitalization | 9.6m USD |
| Shares Outstanding | 2 230 000 |
| Percentage of Shares Shorted | 2.09% |
Company Profile
Moleculin Biotech Inc
Country
Industry
Market Cap
Dividend Yield
Description
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2016-06-02. The firm has a pipeline of clinical programs for the treatment of highly resistant cancers and viruses. The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066 Portfolio (including lead drug candidates WP1066 and WP1220) represents a class of agents capable of hitting multiple targets, including the activated form of a key oncogenic transcription factor, STAT3. WP1066 is its flagship Immune/Transcription Modulator. An analog of WP1066, referred to as WP1220, is related to the use of the molecule in the topical treatment of psoriasis. The firm's WP1122 Portfolio and similar molecules focused on inhibitors of glycolysis and glycosylation.
You don't have any saved screeners yet
